This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.
Caitlin Smare, MSc
Advertisement
Articles by Caitlin Smare, MSc
Advertisement
Latest Updated Articles
- Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States
Published: August 24th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
3
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
4
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
5
